Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen ESA Sales Dive In The Biotech’s “Toughest” Year

Executive Summary

Sales of Amgen's Aranesp and Epogen took a hit in the fourth quarter as the safety of erythropoiesis-stimulating agents was questioned, Amgen reported during its fourth quarter and year-end earnings call Jan. 24. Going into 2008, the company will develop a risk management plan and other strategies to help address the situation

You may also be interested in...

CMS Begins National Coverage Determination Process For ESAs In The Renal Setting

The opening of a national coverage analysis comes with a public request for CMS to establish Medicare coverage limitations for ESA use in pre-dialysis and dialysis renal disease patient populations.

FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling

FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement

As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears

Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts